Literature DB >> 32472178

[Mobile apps and their usage in rheumatology].

M Krusche1, N Ruffer2, M Grahammer3, J Knitza4.   

Abstract

The increasing use of smartphones is accompanied by a significant increase in the use of mobile applications (apps). Chronically ill patients could permanently profit from this development.This development is fuelled by the Digital Healthcare Act (DVG), whereby patients have a legal claim to certain apps, so-called digital health applications (DiGAs), which are reimbursed by the statutory health insurance companies. Especially in the field of rheumatology, there are various opportunities to implement apps in the management of chronic diseases and their comorbidities. Furthermore, rheumatic patients and rheumatologists are becoming interested in apps and are willing to use them in the daily routine. This article tries to shed light on the chances and risks of apps and gives a first insight into the digital landscape of rheumatology apps in Germany.

Entities:  

Keywords:  Digital health; Mobile applications; Rheumatology; eHealth; mHealth

Year:  2020        PMID: 32472178     DOI: 10.1007/s00393-020-00822-2

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  3 in total

Review 1.  [Perspectives for rheumatological health services research at the German Rheumatism Research Center].

Authors:  K Albrecht; F Milatz; J Callhoff; I Redeker; K Minden; A Strangfeld; A Regierer
Journal:  Z Rheumatol       Date:  2020-12-01       Impact factor: 1.372

2.  Digitization in gynecology and obstetrics in times of COVID-19: Results of a national survey.

Authors:  Stefan Hertling; Doreen Hertling; Franziska Loos; David Martin; Isabel Graul
Journal:  Internet Interv       Date:  2021-11-11

3.  Acceptance of Telerheumatology by Rheumatologists and General Practitioners in Germany: Nationwide Cross-sectional Survey Study.

Authors:  Felix Muehlensiepen; Johannes Knitza; Wenke Marquardt; Jennifer Engler; Axel Hueber; Martin Welcker
Journal:  J Med Internet Res       Date:  2021-03-29       Impact factor: 5.428

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.